Navigation Links
3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
Date:6/29/2012

MENLO PARK, Calif., June 29, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology.  Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development.

"With our lead antiviral program entering the clinic in the next year, we are committed to building a strong pipeline.  Doug's extensive experience in target identification and prosecution and his track record of successful early-stage drug development will be instrumental to our continued growth," said George Kemble, PhD, 3-V's Chief Scientific Officer.

"I look forward to building upon the early successes of 3-V and developing the next generation of antiviral compounds with this team," said Dr. Buckley.  "3-V has taken a novel approach to antiviral therapies that are less likely to allow viral resistance to develop.  In addition, this approach opens up the possibility of developing high-value therapeutics in other therapeutic areas, making 3-V a compelling story." 

Dr. Buckley joins 3-V from Exelixis, Inc., where he served most recently as Vice President of Biochemistry.  In that role, he led research and discovery teams responsible for delivering over thirty IND-ready compounds to Exelixis' internal pipeline and to external partnerships.  Also during his tenure at Exelixis, Dr. Buckley contributed to the New Drug Application filing for cabozantinib (XL 184).   Prior to Exelixis, Dr. Buckley was the Department Head of Protein Chemistry and Process Development at Scios, Inc., where he was responsible for process and assay development for two marketed biotherapeutic products (Fiblast® (trafermin) and NATRECOR® (nesiritide)).  Doug received his AB in Chemistry and Economics from Bowdoin College, his PhD in Endocrinology from the Hormone Research Laboratory at the University of California, San Francisco, and his post-doctoral training in the Molecular Biology Department at Massachusetts General Hospital and the Department of Genetics at Harvard Medical School.  Doug serves on the Astia Life Sciences Board as an advisor to women entrepreneurs starting life sciences companies and as a scientific advisor to Woodside Capital Partners.

About 3-V Biosciences

3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, a high barrier to resistance and efficacy against emergent viral strains.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information

Stephen R. Brady
Chief Business Officer
650-561-8600


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
2. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
3. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
4. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
5. Oligonucleotide Delivery: Biology, Engineering and Development Conference
6. GW announces creation of Computational Biology Institute to conduct integrated research
7. MARC travel award announced for the 2012 GSA Yeast Genetics and Molecular Biology Meeting
8. Infection biology: The elusive third factor
9. Tips from the Journals of the American Society for Microbiology
10. MARC travel awards announced for the Society for Developmental Biology 71st Annual Meeting
11. The American Society for Microbiology honors Anthony R. Richardson
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology: